Edgewise Therapeutics (EWTX) Profit After Tax (2020 - 2026)

Edgewise Therapeutics has reported Profit After Tax for 7 years, with the latest figure at -$49.9 million in Q1 2026.

• Quarterly Profit After Tax fell 22.41% year-over-year to -$49.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$177.2 million (down 21.31% YoY) and the FY2025 annual result came in at -$167.8 million, down 25.4% from the prior year.
• Profit After Tax climbed to -$49.9 million in Q1 2026 per EWTX's latest filing, from -$50.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$14.7 million in Q1 2022 and troughed at -$50.5 million in Q4 2025.
• A 5-year average of -$30.5 million and a median of -$28.7 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax tumbled 115.11% in 2022, then fell 14.66% in 2025.
• Over 5 years, Profit After Tax stood at -$20.3 million in 2022, then sank by 41.63% to -$28.7 million in 2023, then slumped by 38.25% to -$39.7 million in 2024, then declined by 27.32% to -$50.5 million in 2025, then rose by 1.1% to -$49.9 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$49.9 million, -$50.5 million, and -$40.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.